Eli Lilly and Company (NYSE:LLY) Shares Bought by Financial Security Advisor Inc.

Financial Security Advisor Inc. raised its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 0.4% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 4,225 shares of the company’s stock after acquiring an additional 18 shares during the quarter. Eli Lilly and Company makes up 0.9% of Financial Security Advisor Inc.’s investment portfolio, making the stock its 21st biggest holding. Financial Security Advisor Inc.’s holdings in Eli Lilly and Company were worth $3,743,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in LLY. China Universal Asset Management Co. Ltd. increased its position in shares of Eli Lilly and Company by 19.6% during the first quarter. China Universal Asset Management Co. Ltd. now owns 9,897 shares of the company’s stock worth $7,699,000 after purchasing an additional 1,620 shares in the last quarter. Quent Capital LLC raised its stake in shares of Eli Lilly and Company by 5.3% during the first quarter. Quent Capital LLC now owns 4,943 shares of the company’s stock worth $3,846,000 after purchasing an additional 249 shares during the last quarter. Clarity Capital Partners LLC purchased a new position in Eli Lilly and Company in the 1st quarter valued at $303,000. Embree Financial Group raised its position in Eli Lilly and Company by 26.0% during the 1st quarter. Embree Financial Group now owns 862 shares of the company’s stock worth $671,000 after buying an additional 178 shares during the last quarter. Finally, Signaturefd LLC boosted its holdings in shares of Eli Lilly and Company by 6.5% in the first quarter. Signaturefd LLC now owns 25,527 shares of the company’s stock valued at $19,859,000 after acquiring an additional 1,554 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

LLY opened at $806.60 on Wednesday. The company has a current ratio of 1.27, a quick ratio of 0.97 and a debt-to-equity ratio of 2.03. Eli Lilly and Company has a twelve month low of $561.65 and a twelve month high of $972.53. The business’s 50 day moving average is $905.20 and its 200-day moving average is $867.96. The stock has a market cap of $765.72 billion, a PE ratio of 87.20, a price-to-earnings-growth ratio of 3.09 and a beta of 0.43.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). The firm had revenue of $11.44 billion for the quarter, compared to the consensus estimate of $12.09 billion. Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The business’s revenue for the quarter was up 20.4% compared to the same quarter last year. During the same period in the previous year, the business posted $0.10 earnings per share. On average, analysts predict that Eli Lilly and Company will post 13.23 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be given a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 0.64%. The ex-dividend date is Friday, November 15th. Eli Lilly and Company’s payout ratio is presently 56.22%.

Wall Street Analyst Weigh In

LLY has been the topic of several recent analyst reports. BMO Capital Markets upped their price objective on shares of Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a research note on Friday, August 9th. Redburn Atlantic raised Eli Lilly and Company to a “hold” rating in a research note on Monday. Wells Fargo & Company increased their price objective on shares of Eli Lilly and Company from $875.00 to $1,000.00 and gave the stock an “overweight” rating in a report on Friday, August 9th. Barclays cut their target price on Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating on the stock in a research report on Thursday, October 31st. Finally, Truist Financial boosted their price objective on shares of Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the stock a “buy” rating in a research note on Thursday, October 10th. Four research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $1,008.41.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.